Vinpocetine CAS:42971-09-5

Vinpocetine

CAS No: 42971-09-5
Product Name: Vinpocetine
Other Name:
Vinpocetine
(3α,16α)-Eburnamenine-14-carboxylic acid ethyl ester
Eburnamenine-14-carboxylic acid ethyl ester
 
Density: 1.3±0.1 g/cm3
Boiling Point: 419.5±45.0 °C at 760 mmHg
Melting Point: 147-153ºC dec
Molecular Formula: C22H26N2O2
Molecular Weight: 350.454
Flash Point: 207.5±28.7 °C
Exact Mass: 350.199432
PSA: 34.47000
LogP: 5.14
Vapour Pressure: 0.0±1.0 mmHg at 25°C
Index of Refraction: 1.666
 
Specification
Appearance: White or off-white crystalline powder
Assay: ≥99.0%
Water: ≤0.50%
 
Application
It is used to improve various symptoms induced by sequelae of cerebral infarction, sequelae of cerebral hemorrhage, and cerebral arteriosclerosis.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



We are professional Vinpocetine manufacturer and Eburnamenine-14-carboxylic acid ethyl ester supplier in China, We offer quality (3α,16α)-Eburnamenine-14-carboxylic acid ethyl ester you can fully trust, also we have India factory and producer of Eburnamenine-14-carboxylic acid ethyl ester,Pls send inquiry of Vinpocetine CAS:42971-09-5 to info@nbinno.com if you have any interests, thank you!


Related News: In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.2-Fluoro-4-(trifluoromethyl)benzaldehyde CAS:89763-93-9 In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.3-Morpholino-1-(4-(2-oxopiperidin-1-yl)phenyl)-5,6-dihydropyridin-2(1H)-one CAS:545445-44-1 Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.N-(4-(9-phenyl-9H-fluoren-9-yl)phenyl)-[1,1'-biphenyl]-4-amine Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.